---
title: "Xoma says algae-based process cuts boron in Hoganas wastewater by up to 86%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290162904.md"
description: "Xoma reported preliminary test results showing its microalgae-based treatment reduced boron in Höganäs process water by up to 86%. The testing, involving Chlorella vulgaris, extends work first disclosed on April 10, 2026. Next steps are currently under review with Höganäs."
datetime: "2026-06-18T08:14:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290162904.md)
  - [en](https://longbridge.com/en/news/290162904.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290162904.md)
generator: "portal-rs"
---

# Xoma says algae-based process cuts boron in Hoganas wastewater by up to 86%

-   Xoma reported preliminary test results for its microalgae-based treatment on Höganäs process water. \* Chlorella vulgaris achieved boron reduction of up to 86% in the trials. \* Testing extended work first disclosed on April 10, 2026; next steps under review with Höganäs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xoma AB published the original content used to generate this news brief via Cision (Ref. ID: 202606180413BITN\_\_**UKPR**SV\_20260618-BIT-9500-0) on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [XOMA.US](https://longbridge.com/en/quote/XOMA.US.md)

## Related News & Research

- [LGND: XOMA acquisition doubled the portfolio and set the stage for accelerated, diversified growth](https://longbridge.com/en/news/297069508.md)
- [Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital](https://longbridge.com/en/news/297072983.md)
- [PharmAla Biotech says USPTO grants US patent for enantioselective MDMA, MBDB processes](https://longbridge.com/en/news/296608164.md)
- [Ligand targets $150-$250 million in annual investments as royalty revenue tops $225 million in 2026 guidance](https://longbridge.com/en/news/297061481.md)
- [Bioextrax patent application enters regulatory review for new molasses-based PHA process](https://longbridge.com/en/news/296315743.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**